[144] Maplebear Inc. SEC Filing
Maplebear Inc. filed a Form 144 reporting a proposed sale of 3,546 common shares, to be executed through Charles Schwab & Co., with an aggregate market value of $150,315.00 and an approximate sale date of 09/22/2025. The filing states these shares were acquired on 08/15/2025 as a Restricted Stock Lapse from Maplebear, Inc., with payment characterized as Equity Compensation. The issuer has 263,438,274 shares outstanding. The filer also disclosed prior sales by the same seller within three months: 4,680 shares on 07/21/2025 for $230,069.00 and 3,544 shares on 08/19/2025 for $161,784.00. The notice includes the standard representation that the seller is not aware of any undisclosed material adverse information.
- Disclosure compliance: Form 144 provides required details (acquisition date, nature, broker, sale date and aggregate value).
- Small relative size: 3,546 shares represent a very small fraction of the 263,438,274 shares outstanding, limiting apparent market impact.
- None.
Insights
TL;DR: Routine insider sale of vested restricted stock; small in scale versus total outstanding shares.
The filing documents a planned sale of 3,546 common shares acquired via a restricted stock lapse on 08/15/2025 and slated for sale on 09/22/2025 through Charles Schwab. The total value reported is $150,315, which represents a vanishingly small fraction of the issuer's 263,438,274 shares outstanding, indicating limited direct dilution or market impact. Recent nearby transactions by the same seller are disclosed, consistent with routine disposition of vested equity.
TL;DR: Disclosure follows Rule 144 requirements; provides necessary transparency on timing and origin of securities.
The Form 144 clearly states the nature of acquisition (Restricted Stock Lapse) and payment type (Equity Compensation), and identifies the broker and planned sale date. These elements satisfy public disclosure expectations for insider dispositions under Rule 144. The seller's certification regarding lack of undisclosed material adverse information is present as required.